Physician profile
Claudia Perez-Tamayo
NPI 1366403537
$4,012.46
in general payments reported to CMS, 2019-2025
50 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 93% of Therapeutic Radiology providers received nationally (typical 2025 total: $179).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $72.47 · 2021: $152 · 2022: $248 · 2023: $548 · 2024: $922 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,223.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $367.68 | 2021-2025 | Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $333.75 | 2022-2025 | |
| Janssen Biotech, INC. | $236.74 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $212.27 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $201.85 | 2019-2025 | Libtayo |
| Novocure INC. | $147.15 | 2024-2025 | Optune Lua (Novottf-200t) |
| Pharmacosmos Therapeutics INC. | $146.85 | 2024-2025 | Monoferric, Cosela |
| Daiichi Sankyo INC. | $143.99 | 2019-2025 | Enhertu |
| Beone Medicines USA, INC. | $128.32 | 2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $125.54 | 2019-2025 | |
| Amgen INC. | $122.17 | 2025 | Imdelltra (Amg757) |
| Incyte Corporation | $117.16 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Genentech USA, INC. | $112.72 | 2022-2024 | Lunsumio, Polivy, Columvi |
| Tersera Therapeutics LLC | $108.78 | 2023-2024 | Zoladex, Xermelo |
| Jazz Pharmaceuticals INC. | $92.33 | 2024-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $89.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.26 | 2023-2025 | Alunbrig, Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $83.28 | 2021-2024 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $80.92 | 2021-2023 | Imbruvica |
| Stemline Therapeutics INC. | $76.53 | 2024-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $66.86 | 2021-2025 | Onivyde, Tazverik |
| Sobi, INC | $64.29 | 2024-2025 | |
| Pfizer INC. | $55.07 | 2021-2025 | |
| Abbvie INC. | $55.07 | 2024-2025 | |
| Exelixis INC. | $53.17 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $51.16 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $48.14 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.05 | 2019-2025 | Opdivo |
| Array Biopharma INC | $47.65 | 2025 | Lorbrena, Xalkori, Mektovi |
| Tesaro, INC. | $44.36 | 2019 | |
| Gilead Sciences, INC. | $40.39 | 2024 | |
| Genmab U.S., INC. | $37.85 | 2023-2025 | Tivdak |
| Sumitomo Pharma America, INC. | $36.17 | 2023-2025 | Orgovyx |
| Kite Pharma, INC. | $31.33 | 2022 | |
| Spectrum Pharmaceuticals INC. | $29.94 | 2023-2025 | Rolvedon |
| Dendreon Pharmaceuticals LLC | $29.53 | 2024-2025 | Provenge |
| Seagen INC. | $29.07 | 2019-2022 | |
| Organon LLC | $23.38 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $23.10 | 2024 | Amtagvi |
| Epizyme, INC. | $22.59 | 2021 | |
| Springworks Therapeutics, INC. | $20.08 | 2024 | Ogsiveo |
| G1 Therapeutics, INC. | $19.00 | 2022 | |
| Mirati Therapeutics, INC. | $16.77 | 2024 | Krazati |
| Acceleron Pharma, INC. | $16.61 | 2020 | |
| Sirtex Medical INC | $16.12 | 2024 | Sir-Spheres Microspheres |
| Acrotech Biopharma INC. | $15.92 | 2023 | Beleodaq |
| Celgene Corporation | $14.47 | 2019 | |
| Adaptive Biotechnologies Corporation | $14.38 | 2025 | Clonoseq |
| Verity Pharmaceuticals INC. | $14.38 | 2023 | Trelstar |
| Verastem, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Perez-Tamayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.